银屑病和其治疗相关的肿瘤患病风险(2)
[10] Pouplard C,Brenaut E,Horreau C, of cancer in psoriasis:A systematic review and meta-analysis of epidemiological studies[J].J Eur Acad Dermatol Venereol,2013,27(Suppl 3):36-46.
[11] Egeberg A,Thyssen JP,Gislason GH, cancer in patients with psoriasis[J].J Eur Acad Dermatol Venereol,2016,30(8):1349-1353.
[12] Dai H,Li WQ,Qureshi AA, history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States:A population-based cohort study[J].J Am Acad Dermatol,2016,75(4):731-735.
[13] Stern RS,PUVA Follow-Up risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy:A 30-year prospective study[J].J Am Acad Dermatol,2012,66(4):553-562.
[14] Archier E,Devaux S,Castela E, risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis:A systematic literature review[J].J Eur Acad Dermatol Venereol,2012,Suppl 3:22-31.
[15] Hearn RM,Kerr AC,Rahim KF, of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy[J].Br J Dermatol,2008,159(4):931-935.
[16] Lim JL,Stern RS.High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients[J].J Investig Dermatol,2005,124(3):505-513.
[17] Salliot C,van der Heijde safety of methotrexate monotherapy in patients with rheumatoid arthritis:A systematic literature research[J].Ann Rheum Dis,2009,68(7):1100-1104.
[18] Bewtra M,Lewis on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease[J].Expert Rev Clin Immunol,2010,6(4):621-631.
[19] Stern risk in psoriasis:Results of the PUVA follow-up study[J].Arch Dermatol,2006,142(9):1132-1135.
[20] Mazaud C,Fardet risk of and determinants for adverse events of methotrexate prescribed at a low dose:A systematic review and meta-analysis of randomized,placebo- controlled trials[J].Br J Dermatol,2017,177(4):978-986.
[21] Warren RB,Mrowietz U,von Kiedrowski R,etal.An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP):A 52 week,multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,389():528-537.
[22] Polesie S,Gillstedt M,S?nnergren HH, treatment and risk for cutaneous malignant melanoma:A retrospective comparative registry-based cohort study[J].Br J Dermatol,2017,176(6):1492-1499.
[23] Fiorentino D,Ho V,Lebwohl MG, of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry[J].J Am Acad Dermatol,2017,77(5):845-854.
[24] Lange E,Blizzard L,Venn A, anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients:A retrospective cohort study[J].Rheumatology (Oxford),2016,55(9):1594-1600.
[25] Paul CF,Ho VC,McGeown C, of malignancies in psoriasis patients treated with cyclosporine:A 5 year cohort study[J].J Investig Dermatol,2003,120(2):211-216.
[26] Marcil I,Stern cancer of the skin in patients given PUVA and ciclosporin:Nested cohort crossover study[J].Lancet,2001,358(9287):1042-1045.
[27] Jabbar-Lopez ZK,Yiu ZZN,Ward V, evaluation of biologic therapy options for psoriasis:A systematic review and network meta-analysis[J].J Invest Dermatol,2017,137(8):1646-1654.
[28] Gottlieb AB,Kalb RE,Langley RG, observations in psoriasis patients enrolled in an international registry (PSOLAR):Experience with infliximab and other systemic and biologic therapies[J].J Drugs Dermatol,2014,13(12):1441-1448.
[29] Garcia-Doval I,Cohen AD,Cazzaniga S, of serious infections,cutaneous bacterial infections,and granulomatous infections in psoriasis patients treated with anti-tumor necrosis factor agents versus classic therapies:Prospective metaanalysis of Psonet registries[J].J Am Acad Dermatol,2017,76(2):299-308.
[30] Warren RB,Smith CH,Yiu ZZN, drug survival of biologic therapies for the treatment of psoriasis:A prospective observational cohort study from the British association of dermato-logists biologic interventions register (BADBIR) [J].J Invest Dermatol,2015,135(11):2632-2640.
[31] Asgari MM,Ray GT,Geier JL, rates in a large cohort of patients with systemically treated psoriasis in a managed care population[J].J Am Acad Dermatol,2017,76(4):632-638.
[32] Geller S,Xu H,Lebwohl M, risk and recurrence with psoriasis and its treatments:A concise update[J].Am J Clin Dermatol,2018,19(3):363-375.
[33] Siegel CA,Marden SM,Persing SM, of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn′s disease:A meta-analysis[J].Clin Gastroenterol Hepatol,2009,7(8):874-881.
[34] Deepak P,Sifuentes H,Sherid M, non-Hodgkin′s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors:Results of the REFURBISH study[J].Am J Gastroenterol,2013,108(1):99-105.
[35] Dommasch ED,Abuabara K,Shin DB,etal.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease:A systematic review and meta-analysis of randomized controlled trials[J].J Am Acad Dermatol,2011,64(6):1035-1350.
文章来源:《中国肿瘤生物治疗杂志》 网址: http://www.zgzlswzlzz.cn/qikandaodu/2020/1120/459.html
上一篇:冬虫夏草,科学的笑话
下一篇:糖尿病肾病的生物治疗及研究进展